Evidence map›Paper›PMID 35786898›Full record

ArticleJournal of agricultural and food chemistry2022

4″-Sulfation Is the Major Metabolic Pathway of Epigallocatechin-3-gallate in Humans: Characterization of Metabolites, Enzymatic Analysis, and Pharmacokinetic Profiling.

Akane Hayashi, Shimpei Terasaka, Yuko Nukada, Akiyo Kameyama, Masayuki Yamane, Ryuta Shioi, Masazumi Iwashita, Kohjiro Hashizume, Osamu Morita

Open access · hybridAbstract read
In one paragraph

Article in Journal of agricultural and food chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-Phytomedicine plus : international journal of phytotherapy and phytopharmacology · 2023
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Akane HayashiSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.ORCID 0000-0002-8762-4136
Shimpei TerasakaSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Yuko NukadaSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Akiyo KameyamaSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Masayuki YamaneSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Ryuta ShioiBiological Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Masazumi IwashitaBiological Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Kohjiro HashizumeBiological Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Osamu MoritaSafety Science Laboratories, Kao Corporation, Tochigi 321-3497, Japan.
Kao Corporation (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigallocatechin-3-gallate (EGCG), a major green tea polyphenol, has beneficial effects on human health. This study aimed to elucidate the detailed EGCG sulfation process to better understand its phase II metabolism, a process required to maximize its health benefits. Results show that kinetic activity of sulfation in the human liver and intestinal cytosol is 2-fold and 60- to 300-fold higher than that of methylation and glucuronidation, respectively, suggesting sulfation as the key metabolic pathway. Moreover, SULT1A1 and SULT1A3 are responsible for sulfation in the liver and intestine, respectively. Additionally, our human ingestion study revealed that the concentration of EGCG-4″-sulfate in human plasma (

Indexed as

CatechinHumansMetabolic Networks and PathwaysSulfatesTeaCatechinepigallocatechin gallateSulfatesTeabioavailabilityepigallocatechin-3-gallatemetabolismpharmacokineticssulfation

Identifiers

PMID35786898
PMCPMC9284555
OpenAlexW4283812762

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.